scholarly journals Faculty Opinions recommendation of Efficacy of a combined treatment of botulinum toxin and intensive physiotherapy in hereditary spastic paraplegia.

2021 ◽  
Author(s):  
Alexandra Durr
Keyword(s):  
Botulinum Toxin ◽  
Hereditary Spastic Paraplegia ◽  
Combined Treatment ◽  
Spastic Paraplegia ◽  
Intensive Physiotherapy

scholarly journals Efficacy of a Combined Treatment of Botulinum Toxin and Intensive Physiotherapy in Hereditary Spastic Paraplegia

2020 ◽  
Vol 14 ◽  
Author(s):  
Gabriella Paparella ◽  
Marinela Vavla ◽  
Lisa Bernardi ◽  
Giulia Girardi ◽  
Cristina Stefan ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Hereditary Spastic Paraplegia ◽  
Combined Treatment ◽  
Spastic Paraplegia ◽  
Intensive Physiotherapy

Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia — The SPASTOX Trial

2021 ◽  
Author(s):  
Fabricio Diniz de Lima ◽  
Ingrid Faber ◽  
Katiane R. Servelhere ◽  
Maria Fernanda R. Bittar ◽  
Alberto R.M. Martinez ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Randomized Trial ◽  
Hereditary Spastic Paraplegia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spastic Paraplegia

scholarly journals Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

2018 ◽  
Vol 76 (3) ◽  
pp. 183-188 ◽  
Author(s):  
Katiane R. Servelhere ◽  
Ingrid Faber ◽  
Alberto Martinez ◽  
Renato Nickel ◽  
Adriana Moro ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Hereditary Spastic Paraplegia ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Motor Symptoms ◽  
Spastic Paraplegia ◽  
Adductor Muscles ◽  
Before And After ◽  
Motor Improvement ◽  
Non Motor Symptoms

ABSTRACT Motor and non-motor manifestations are common and disabling features of hereditary spastic paraplegia (HSP). Botulinum toxin type A (Btx-A) is considered effective for spasticity and may improve gait in these patients. Little is known about the effects of Btx-A on non-motor symptoms in HSP patients. Objective To assess the efficacy of Btx-A on motor and non-motor manifestations in HSP patients. Methods Thirty-three adult patients with a clinical and molecular diagnosis of HSP were evaluated before and after Btx-A injections. Results Mean age was 41.7 ± 13.6 years and there were 18 women. Most patients had a pure phenotype and SPG4 was the most frequent genotype. The Btx-A injections resulted in a decrease in spasticity at the adductor muscles, and no other motor measure was significantly modified. In contrast, fatigue scores were significantly reduced after Btx-A injections. Conclusion Btx-A injections resulted in no significant functional motor improvement for HSP, but fatigue improved after treatment.

Sign in / Sign up

Export Citation Format

Share Document